Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.

Lu DJ, Luu M, Nguyen AT, Scher KS, Clair JM, Mita A, Shiao SL, Ho AS, Zumsteg ZS.

Oral Oncol. 2019 Nov 5;99:104472. doi: 10.1016/j.oraloncology.2019.104472. [Epub ahead of print]

PMID:
31704556
2.

Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy.

Sittig MP, Luu M, Yoshida EJ, Scher K, Mita A, Shiao SL, Lu DJ, Mallen-St Clair J, Ho AS, Zumsteg ZS.

Clin Otolaryngol. 2019 Oct 29. doi: 10.1111/coa.13467. [Epub ahead of print]

PMID:
31661188
3.

Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?

Yoshida EJ, Luu M, Mallen-St Clair J, Mita AC, Scher KS, Lu DJ, Nguyen AT, Shiao SL, Ho AS, Zumsteg ZS.

Cancer. 2019 Sep 19. doi: 10.1002/cncr.32501. [Epub ahead of print]

PMID:
31536144
4.

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M.

PLoS One. 2019 Sep 17;14(9):e0221994. doi: 10.1371/journal.pone.0221994. eCollection 2019.

5.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.

Hong D, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E.

Oncology. 2019;97(2):102-111. doi: 10.1159/000500571. Epub 2019 Jun 21.

6.

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DJ, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Oct 1;30(10):1669. doi: 10.1093/annonc/mdz172. No abstract available.

7.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J.

Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.

PMID:
31088831
8.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

9.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.

10.

Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.

Ou Y, Xu Y, Gore L, Harvey RD, Mita A, Papadopoulos KP, Wang Z, Cutler RE Jr, Pinchasik DE, Tsimberidou AM.

Br J Clin Pharmacol. 2019 Mar;85(3):530-539. doi: 10.1111/bcp.13817. Epub 2018 Dec 25.

PMID:
30428505
11.

Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation.

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, Lu DP, Shiao SL, Mallen-St Clair J, Ho AS.

Ann Oncol. 2019 Jan 1;30(1):76-84. doi: 10.1093/annonc/mdy490. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1669.

PMID:
30395159
12.

Human papillomavirus-associated oropharyngeal cancer among patients aged 70 and older: Dramatically increased prevalence and clinical implications.

Lu DJ, Luu M, Mita A, Scher K, Shiao SL, Yoshida EP, Sittig MP, Mallen-St Clair J, Ho AS, Zumsteg ZS.

Eur J Cancer. 2018 Nov;103:195-204. doi: 10.1016/j.ejca.2018.08.015. Epub 2018 Sep 27.

PMID:
30268920
13.

Quantitative survival impact of composite treatment delays in head and neck cancer.

Ho AS, Kim S, Tighiouart M, Mita A, Scher KS, Epstein JB, Laury A, Prasad R, Ali N, Patio C, Clair JM, Zumsteg ZS.

Cancer. 2018 Aug 1;124(15):3154-3162. doi: 10.1002/cncr.31533. Epub 2018 May 9.

14.

Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.

Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z.

PMID:
29736778
15.

Divergent antioxidant capacity of human islet cell subsets: A potential cause of beta-cell vulnerability in diabetes and islet transplantation.

Miki A, Ricordi C, Sakuma Y, Yamamoto T, Misawa R, Mita A, Molano RD, Vaziri ND, Pileggi A, Ichii H.

PLoS One. 2018 May 3;13(5):e0196570. doi: 10.1371/journal.pone.0196570. eCollection 2018.

16.

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N.

Exp Hematol Oncol. 2018 Apr 13;7:9. doi: 10.1186/s40164-018-0101-1. eCollection 2018.

17.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S.

Invest New Drugs. 2019 Feb;37(1):76-86. doi: 10.1007/s10637-018-0602-0. Epub 2018 Apr 18.

PMID:
29667134
18.

Rorschach Evaluation of Personality and Emotional Characteristics in Adolescents With Migraine Versus Epilepsy and Controls.

Balottin L, Mannarini S, Candeloro D, Mita A, Chiappedi M, Balottin U.

Front Neurol. 2018 Mar 20;9:160. doi: 10.3389/fneur.2018.00160. eCollection 2018.

19.

Perspectives in Head and Neck Medical Oncology.

Amanam I, Gupta R, Mita A, Scher K, Massarelli E.

Cancer Treat Res. 2018;174:163-185. doi: 10.1007/978-3-319-65421-8_10.

PMID:
29435842
20.

Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Ho AS, Zumsteg ZS.

Head Neck. 2018 Jun;40(6):1228-1236. doi: 10.1002/hed.25100. Epub 2018 Feb 8.

PMID:
29417700
21.

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF.

Cell. 2018 Feb 8;172(4):825-840.e18. doi: 10.1016/j.cell.2017.12.026. Epub 2018 Jan 11.

22.

Difficulty in positive diagnosis of ascites and in differential diagnosis of a pulmonary tumor.

ForŢofoiu MC, Popescu DM, Pădureanu V, Dobrinescu AC, Dobrinescu AG, Mită A, Foarfă MC, Bălă VS, Muşetescu AE, Ionovici N, ForŢofoiu M.

Rom J Morphol Embryol. 2017;58(3):1057-1064.

23.

Association of Quantitative Metastatic Lymph Node Burden With Survival in Hypopharyngeal and Laryngeal Cancer.

Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, Patio C, Mallen-St Clair J, Van Eyk JE, Zumsteg ZS.

JAMA Oncol. 2018 Jul 1;4(7):985-989. doi: 10.1001/jamaoncol.2017.3852.

24.

Markerless Knee Joint Position Measurement Using Depth Data during Stair Walking.

Ogawa A, Mita A, Yorozu A, Takahashi M.

Sensors (Basel). 2017 Nov 22;17(11). pii: E2698. doi: 10.3390/s17112698.

25.

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Oncotarget. 2017 Sep 30;8(49):86769-86783. doi: 10.18632/oncotarget.21423. eCollection 2017 Oct 17.

26.

Facility Volume and Survival in Nasopharyngeal Carcinoma.

Yoshida EJ, Luu M, David JM, Kim S, Mita A, Scher K, Shiao SL, Tighiouart M, Lee NY, Ho AS, Zumsteg ZS.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):408-417. doi: 10.1016/j.ijrobp.2017.09.038. Epub 2017 Sep 28.

PMID:
29100787
27.

Predictors of survival in head and neck mucosal melanoma.

Schmidt MQ, David J, Yoshida EJ, Scher K, Mita A, Shiao SL, Ho AS, Zumsteg ZS.

Oral Oncol. 2017 Oct;73:36-42. doi: 10.1016/j.oraloncology.2017.08.002. Epub 2017 Aug 10.

PMID:
28939074
28.

Metastatic Lymph Node Burden and Survival in Oral Cavity Cancer.

Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Van Eyk JE, Zumsteg ZS.

J Clin Oncol. 2017 Nov 1;35(31):3601-3609. doi: 10.1200/JCO.2016.71.1176. Epub 2017 Sep 7.

29.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI.

Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31.

30.

Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.

Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 Dec 1;123(23):4583-4593. doi: 10.1002/cncr.30933. Epub 2017 Aug 17.

31.

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors.

Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM.

Onco Targets Ther. 2017 Jun 27;10:3177-3186. doi: 10.2147/OTT.S128547. eCollection 2017.

32.

Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.

Tabatabai R, Linhares Y, Bolos D, Mita M, Mita A.

Target Oncol. 2017 Oct;12(5):623-641. doi: 10.1007/s11523-017-0507-4. Review.

PMID:
28653295
33.

Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer.

David JM, Ho AS, Luu M, Yoshida EJ, Kim S, Mita AC, Scher KS, Shiao SL, Tighiouart M, Zumsteg ZS.

Cancer. 2017 Oct 15;123(20):3933-3942. doi: 10.1002/cncr.30843. Epub 2017 Jun 22.

34.

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K.

Eur J Cancer. 2017 Aug;81:242. doi: 10.1016/j.ejca.2017.05.003. Epub 2017 Jun 10. No abstract available.

PMID:
28606464
35.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):360.

36.

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.

J Clin Oncol. 2017 Jul 1;35(19):2117-2124. doi: 10.1200/JCO.2016.71.6795. Epub 2017 Apr 4.

37.

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K.

Eur J Cancer. 2017 May;76:36-44. doi: 10.1016/j.ejca.2017.01.024. Epub 2017 Mar 20. Erratum in: Eur J Cancer. 2017 Aug;81:242.

PMID:
28282611
38.

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Mita M, Fu S, Piha-Paul SA, Janku F, Mita A, Natale R, Guo W, Zhao C, Kurzrock R, Naing A.

Invest New Drugs. 2017 Oct;35(5):616-626. doi: 10.1007/s10637-017-0442-3. Epub 2017 Feb 13.

39.

The association between chronic pancreatitis and the iNOS-2087A>G polymorphism.

Pădureanu V, Enescu AŞ, Siloşi I, Forţofoiu M, Enescu A, Bogdan M, Forţofoiu MC, Dumitrescu AG, Tudoraşcu DR, Mita A, Streata I, Ioana M, Petrescu F, Săftoiu A.

Rom J Intern Med. 2017 Jun 1;55(2):89-95. doi: 10.1515/rjim-2017-0009.

PMID:
28125406
40.

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.

Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O.

Cancer Chemother Pharmacol. 2017 Feb;79(2):339-351. doi: 10.1007/s00280-016-3210-8. Epub 2017 Jan 5.

41.

Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.

Zumsteg ZS, Kim S, David JM, Yoshida EJ, Tighiouart M, Shiao SL, Scher K, Mita A, Sherman EJ, Lee NY, Ho AS.

Cancer. 2017 May 1;123(9):1555-1565. doi: 10.1002/cncr.30508. Epub 2016 Dec 21.

42.

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F.

J Thorac Oncol. 2017 Jan;12(1):145-151. doi: 10.1016/j.jtho.2016.09.131. Epub 2016 Sep 30.

43.

Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States.

Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, Jeon C, Goodman MT, Ho AS.

JAMA Oncol. 2016 Dec 1;2(12):1617-1623. doi: 10.1001/jamaoncol.2016.1804.

PMID:
27415639
44.

Impact of Dynamic and Static Load on Bone Around Implants: An Experimental Study in a Rat Model.

Yagihara A, Kawasaki R, Mita A, Takakuda K.

Int J Oral Maxillofac Implants. 2016 May-Jun;31(3):e49-56. doi: 10.11607/jomi.4372.

PMID:
27183082
45.

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Gong J, Sachdev E, Mita AC, Mita MM.

World J Methodol. 2016 Mar 26;6(1):25-42. doi: 10.5662/wjm.v6.i1.25. eCollection 2016 Mar 26. Review.

46.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.

47.

Comparison of fecal pooling methods and DNA extraction kits for the detection of Mycobacterium avium subspecies paratuberculosis.

Mita A, Mori Y, Nakagawa T, Tasaki T, Utiyama K, Mori H.

Microbiologyopen. 2016 Feb;5(1):134-42. doi: 10.1002/mbo3.318. Epub 2015 Dec 15.

48.

Living-Donor Liver Transplantation for Hepatic Metastasis From Meningeal Hemangiopericytoma: A Case Report.

Urata K, Ikegami T, Nakazawa Y, Ohno Y, Kobayashi A, Mita A, Sano K, Kurozumi M, Miyagawa S.

Transplant Proc. 2015 Sep;47(7):2274-7. doi: 10.1016/j.transproceed.2015.06.027.

PMID:
26361698
49.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC.

J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31.

PMID:
26324363
50.

Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.

Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS.

Int J Clin Pharmacol Ther. 2015 Jul;53(7):563-72. doi: 10.5414/CP202359.

PMID:
26073352

Supplemental Content

Support Center